Logo 1 Logo 2

Clinical Trial Details

Trial ID: L3733
Source ID: NCT04373967
Associated Drug: Victoza®.
Title: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes
Acronym:
Status: UNKNOWN
Study Results: NO
Results:
Conditions: Type 2 Diabetes
Interventions: DRUG: Victoza®.|DRUG: Metformin Hydrochloride|DRUG: TQZ2451
Outcome Measures: Primary: glycated hemoglobin (HbA1c), Changes in glycated hemoglobin (HbA1c) relative to baseline., week 0,week 26 | Secondary: Body weight, Changes in body weight relative to baseline., week 0,week 26|Proportion of achieving HbA1c target (<7.0% or ≤6.5%), week 0,week 26|HbA1c change from baseline, week 0,week 14|Changes in fasting venous blood glucose (FPG)., week 0,week 14,week 26|Changes in 2h-Postprandial Blood Glucose(2h-PBG)., week 0,week 14,week 26|Changes in fasting insulin., week 0,week 14,week 26|Changes in fasting C peptide., week 0,week 14,week 26|Changes in systolic blood pressure., week 0,week 14,week 26|Changes in diastolic blood pressure., week 0,week 14,week 26|Number of adverse events and serious adverse events during exposure to trail product., week 0-26|Number of treatment-emergent severe or blood glucose-confirmed symptomatic hypoglycaemic episodes during exposure to trail product., week 0-26|Positive rate of liraglutide anti-drug antibody(ADA)., week 0-26|Percentage of participants with clinically significant change from baseline in vital signs., week 0-26|Percentage of participants with clinically significant change from baseline in laboratory parameters., week 0-26
Sponsor/Collaborators: Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 424
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2020-04-29
Completion Date: 2021-12-02
Results First Posted:
Last Update Posted: 2020-07-08
Locations: The Second Hospital of Anhui Medical University, Hefei, Anhui, 230000, China|The Second People's Hospital of Heifei, Hefei, Anhui, 230000, China|Ma'anshan People's Hospital, Ma'anshan, Anhui, 243000, China|Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, 241000, China|The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, 400000, China|The Ninth People's Hospital of Chongqing, Chongqing, Chongqing, 400000, China|The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, 400000, China|Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, 524000, China|Liuzhou People's Hospital, Liuzhou, Guangxi, 545000, China|The First People's Hospital of Nanning, Nanning, Guangxi, 530000, China|The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, 550000, China|The Third Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050000, China|The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150000, China|The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, 150000, China|The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, 471000, China|Xinxiang Central Hospital, Xinxiang, Henan, 453000, China|People's Hospital of Zhengzhou, Zhengzhou, Henan, 450000, China|The Third People's Hospital of Hebei, Wuhan, Hubei, 430000, China|The Second People's Hospital of Lianyungang, Lianyungang, Jiangsu, 222000, China|Nanjing Drum Tower Hospital, Nanjing, Jiangsu, 210000, China|Nanjing Jiangning Hospital, Nanjing, Jiangsu, 210000, China|Xuzhou Third People's Hospital, Xuzhou, Jiangsu, 221000, China|Nanchang First Hospital, Nanchang, Jiangxi, 330000, China|Affiliated Hospital of Changchun University of Chinese Medicine, Changchun, Jilin, 130000, China|Jilin Province FAW General Hospital, Changchun, Jilin, 130000, China|The Second Hospital of Jilin University, Changchun, Jilin, 130000, China|Meihekou Central Hospital, Tonghua, Jilin, 134000, China|Dalian Municipal Central Hospital Affiliated of Dalian Medical University, Dalian, Liangning, 116000, China|People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, Ningxia, 750000, China|Jinan Central Hospital, Jinan, Shandong, 250000, China|Weifang Traditional Chinese Hospital, Weifang, Shandong, 261000, China|Shanghai Pudong Hospital, Shanghai, Shanghai, 200000, China|Changzhi People's Hospital, Changzhi, Shanxi, 046000, China|Peace Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, 046000, China|Jincheng General Hospital, Jincheng, Shanxi, 048000, China|Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, 030000, China|Shanxi Provincial People's Hospital, Taiyuan, Shanxi, 030000, China|The First Affiliated Hospital of Xi'an Jiaotong Univesity, Xi'an, Shanxi, 710000, China|The First Affiliated Hospital of The Fourth Military Medical University, Xian, Shanxi, 710000, China|The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital), Xian, Shanxi, 710000, China|Yuncheng Central Hospital, Yuncheng, Shanxi, 044000, China|General Hospital of Tianjin Medical University, Tianjin, Tianjin, 300000, China|Tianjin First Central Hospital, Tianjin, Tianjin, 300000, China|First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, 650000, China|Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, 310000, China|Taizhou First People's Hospital, Taizhou, Zhejiang, 318000, China
URL: https://clinicaltrials.gov/show/NCT04373967